Form PTO-1449			Docket Number 316082000121		Application Number 09/194,164				
INFORMATION DISCLOSURE CHARGEN &				ଦ ୁ	Applicant Michael D. Dan et al.				
	(L	lse several sheets i	Inecessary MAN 94	See Research	Filing Date November	r 20, 1998	Group Art Unk	nown	
·	. DEPART DOCUMENTS								
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	Filing D Approp	
CY	1.	06/18/74	3,817,837	Rube	enstein et al.				
1	2.	11/26/74	3,850,752	Schu	urs et al.			-	
	3.	02/17/76	3,939,350	Kror	ick et al.				
	4.	12/07/76	3,996,345	Ulln	an et al.				
	5.	06/23/81	4,275,149	Litm	an et al.				
	6.	07/07/81	4,277,437	Mag	gio				
	7.	12/28/82	4,366,241	Tom	et al.				
	8.	10/21/86	4,618,477	Babu	et al.				
	9.	07/28/87	4,683,195	Mullis et al.					
	10.	07/28/87	4,683,202	Mullis					
	11.	06/28/88	4,754,065	Leve	nson et al.				
	12.	01/24/89	4,800,159	Mullis et al.					
	13.	01/08/91	4,983,586	Bodor					
	14.	03/26/91	5,002,935	Bodor					
	15.	05/21/91	5,017,566	Bodo	or				
	16.	10/06/92	5,153,179	Eibl	_	-	نــــــن		
	17.	12/14/93	5,270,202	Rayo	haudhuri	T ——			
	18.	12/12/95	5,474,755	Hann	a, Jr. et al.				
1	19.	06/25/96	5,530,101	Quee	n et al.				
CY	20.	12/17/96	5,585,089	Quee	n et al.				
-	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Ref.	Date	Document No.	Country		Class	Subclass	Transla YES	ntion NO
CY	21.	04/04/91	WO 91/04014	PCT				·	
CY	22.	04/15/93	WO 93/07286	PCT					
۲۷	23.	03/06/96	0 699 755	Europe					
	EXAMINER: Champy Y DATE CONSIDERED: 4/13/05								
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.									

				•	PTO/SB/08 (2-92) Sheet 2 of 7		
Form PTC)-1449			Docket Number 316082000121	Application Number 09/194,164		
INFO	TAMS	ON DISCLOSURE CHATI	ON CO	Applicant			
1101	IN	AN APPLICATION	1 1888 B		. Dan et al.		
	(U.	se several sheets if necessary	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Filing Date November 20, 1998	Group Art Unknown		
•		ATT (O)	THE D	OCUMENTS			
Examiner Ref. Title							
Initials	Initials No. 24. Marchant, "Contemporary management of breast cancer" Obstetrics and Gynecology						
cY	24.	Clinics of North America (rics and Gynecology		
	25.			ancer" Cancer (1993) 71:1480	<u> </u>		
	26.			o cancer invasion: Strategies			
	20.	intervention" Cancer Res.	-	•	for prevention and		
	27.	Koda et al., "Three step rac	lioimmu	nodiagnosis of colon cancers	using murine and human		
		monoclonal antibodies" An	n. J. Gas	troenterol. (1995) 90: Abstrac	et No. 357.		
	28.	Hall, "Monoclonal antibod	ies at age	e 20: Promise at last?" Science	e (1995) 270:915-916.		
	29.	Schattner, "The origin of a	utoantibo	odies" <i>Immunol. Lett.</i> (1986/1	987) <i>14</i> :143-153.		
	30. Lutz et al., "Naturally occurring autoantibodies to skeletal proteins from human red blood cells" J. Immunol. (1982) 128:1695-1699.						
	31.						
	32.			lymphocytes from a tumor-in	volved lymph node"		
		Cancer Res. (1987) 47:518					
	33.			esponse in patients to glioma			
				orescence" Immunobiol. of P.	roteins and Peptides VI		
		(1991) M. Atassi, ed., Plen					
	34.	Skerra, "Bacterial expression 5:256-262.	on of im	munoglobulin fragments" Cui	rr. Opin. Immunol(1993)		
	35.			on and long-term storage of er			
				nology (1995) 13:1090-1093.			
•	36.			antimelanoma single-chain I			
	tumor-infiltrating lymphocytes" Cancer Res. (1995) 55:3584-3591. 37. Barbas, "Synthetic human antibodies" Nature Med. (1995) 1:837-839.						
	37.						
	38.	Yoshikawa et al., "A huma cancer cells" Jpn. J. Cancer		lonal antibody recognizing a 989) 80:546-553.	surface antigen on stomach		
	39.	Yamaguchi et al., "Cell-sur antibodies" Proc. Natl. Acc		igens of melanoma recognized ISA (1987) 84:2416–2420.	d by human monoclonal		
	40.			cell-reactive human monoclo	nal antibodies using		
^~				actively immunized colorecta			
CY		Cancer Res. (1985) 45:395		•			

EXAMINER: Change HZ	DATE CONSIDERED:	4/13/05
---------------------	------------------	---------

Form PTO-1449 INFORMATION DISCLOSURS CITATION IN AN APPLICATION (Use several sheets if necessary)

Docket Number 316082000121

Application Number 09/194,164

Applicant

Michael D. Dan et al.

Filing Date November 20, 1998

Group Art Unknown

OTHER DOCUMENTS Ref. Title Examiner **Initials** No. Cote et al., "Specificity analysis of human monoclonal antibodies reactive with cell surface 41. CY and intracellular antigens" Proc. Natl. Acad. Sci. USA (1986) 83:2959-2963. Glassy, "Immortalization of human lymphocytes from a tumor-involved lymph node" 42. Cancer Res. (1987) 47:5181-5188. Borup-Christensen et al., "Human-human hybridomas generated with lymphocytes from 43. patients with colorectal cancer" Cancer Detect. Prevent. Suppl. (1987) 1:207-215. Kan-Mitchell et al., "Tumor-reactive human immunoglobulin G monoclonal antibody from a 44. melanoma patient" Cancer Res. (1989) 49:4536-4541. Yoshikawa et al., "Human monoclonal antibody reactive to stomach cancer produced by 45. mouse-human hybridoma technique" Jpn. J. Cancer Res. (1986) 77:1122-1133. Olsson, "Human monoclonal antibodies in experimental cancer research" J. Nat. Cancer 46. Inst. (1985) 75:397-403. Larrick et al., "Prospects for the therapeutic use of human monoclonal antibodies" J. Biol. 47. Response Mod. (1986) 5:379-393. McCabe et al., "Preclinical studies on the pharmacokinetic properties of human monoclonal 48. antibodies to colorectal cancer and their use for detection of tumors" Cancer Res. (1988) *48*:4348-4353. Cohen, "Cancer vaccines get a shot in the arm" Science (1993) 262:841-843. 49. Ditzel et al., "Immunoscintigraphy of colon cancers with the human monoclonal antibody 50. COU-1" Cancer (1994) 73:858-863. Alonso, "Human-human monoclonal antibody directed against tumor surface antigen in the 51. treatment of human malignancy" Am. J. Clin. Oncol. (1991) 14:463-471. Mack et al., "A small bispecific antibody construct expressed as a functional single-chain 52. molecule with high tumor cell cytotoxicity" Proc. Natl. Acad. Sci. USA (1995) 92:7021-7025. Cheresh et al., "Disialoganglioside GD3 on human melanoma serves as a relevant target 53. antigen for monoclonal antibody-mediated tumor cytolysis" Proc. Natl. Acad. Sci USA (1985) 82:5155-5159. Cheresh et al., "Biosynthesis and expression of the disialoganglioside GD2, a relevant target 54. antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis" Cancer Cア Res. (1986) 46:5112-5118.

		· · · · · · · · · · · · · · · · · · ·		
EVAMBIED.	○ 1	. 🔍 🖊	DATE CONSIDERED:	
EXAMINER:	/ \ \ I	1 / ¥	DATE CONSIDERED:	
	1 1 0 0 0	2111		4/12/25
· · · · · · · · · · · · · · · · · · ·		~ // · · · · · · · · · · · · · · · · · ·	L.	

			•	PTO/SB/08 (2-92) Sheet 4 of 7			
Form PTC)-1449		Docket Number 316082000121	Application Number 09/194,164			
INFORMATION DISCLOSURE (TRATION OF IN AN APPLICATION OF IN A THOREOFT OF IN A			Applicant Michael D. Dan et al.				
		AN APPLICATION (1) (1) See several sheets if necessary (1)	Filing Date November 20, 1998	Group Art Unknown			
•		CATEMY & TROUGH					
			OCUMENTS				
Examiner Initials	Ref. No.	Title					
cY	55.	Murakami et al., "Human-human h carcinoma" In Vitro Cell. & Dev. B		es specific to human lung			
	56.	Schadendorf et al., "A novel hetero a human monoclonal antibody" J. 1					
	57.	Pickering et al., "Human monoclon cell carcinoma" Clin. Immunol. Imm					
	58.	Hagiwara et al., "Human x human l autologous cervical carcinoma" Mo		, ,			
	59.	Schlom et al., "Generation of human monoclonal antibodies reactive with human mammary carcinoma cells" <i>Proc. Natl. Acad. Sci.</i> USA (1980) 77:6841-6845.					
	60.	Finn et al., "MUC-1 epithelial tumo Rev. (1995) 145:61-89.					
	61.	Matsumoto et al., "Clinical phase I IgG) against human malignant brain					
	62.	Saleh et al., "Phase II trial of murin human monocyte colony-stimulatin gastrointestinal cancer" Cancer Re.	e monoclonal antibody D612 g factor (rhM-CSF) in patient	combined with recombinant			
	Pastan et al., "Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model" <i>Proc. Natl. Acad. Sci. USA</i> (1995) 92:2765-2769.						
	64. Chaudhuri et al., "Human monoclonal antibody developed against ovarian cancer cell surface antigen" Cancer (1994) 73:1098-1104.						
	65.	Thorpe et al., Monoclonal antibody-toxin conjugates: aiming the magic bullet" Monoclonal Antibodies in Clinical Medicine (1982) Academic Press, pp. 168–201.					
<u> </u>	66.	Vitetta et al., "Redesigning nature's poisons to create anti-tumor reagents" Science (1987) 238:1098–1104.					
	67.	Winter et al., "Man-made antibodie	s" Nature (1991) 349:293–29	9.			
	68.	Olsnes et al., "Chimeric toxins" Pho	armac. Ther. (1982) 15:355–3	381.			
69. Chatal et al., "Clinical prospective study with radioiodinated monoclonal antibodies of against colorectal cancer" Monoclonal Antibodies for Cancer Detection and Therapy Baldwin et al., eds., Academic Press, Chapter 8, pp. 159–180.							

EXAMINER: Charper 2 DATE CONSIDERED: 4/13/0

		-		Sheet 5 of 7			
Form PTO-1449			Docket Number 316082000121	Application Number 09/194,164			
INFORMATION DISCLOSURE OF ATTOMO IN AN APPLICATION			Applicant Michael D. Dan et al.				
	U	See several sheets if necessary) WAN 16 1859	Filing Date November 20, 1998	Group Art Unknown			
•	· Pales a market						
OTHER DOCUMENTS							
Examiner Initials	Ref. No.	Title					
cY	70.	Jansen et al., "Efficiency and toleral human bone marrow transplantation Therapy (1985) Baldwin et al., eds.	ns" Monoclonal Antibodies fo , Academic Press, Chapter 11	or Cancer Detection and , pp. 223–267.			
	71.	Miltenyi et al., "High gradient magi 11:231-238.	netic cell separation with MA	.CS" Cytometry (1990)			
	72.	Glaser et al., "Dissection of the con Immunol. (1992) 149:2607-2614.	nbining site in a humanized a	nti-Tac antibody" J.			
	73.	Tempest et al., "Reshaping a humar syncytial virus infection in vivo" Bi					
	74.	Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the <i>HER2</i> protooncogene" <i>J. Exp. Med.</i> (1992) 175:217-225.					
	75.	Levitt, "Molecular dynamics of native protein" I. Computer simulation of trajectories" J. Mol. Biol. (1983) 168:595-620.					
	76.	Bird et al., "Single-chain antigen-bi		•			
	77.	Posnett et al., "A novel method for 263:1719-1725.		•			
	78.	Tam, "High-density multiple antige antibodies" Meth. Enz. (1989) 168:7		tion of antipeptide			
	79.	Fiedler et al., High level production transgenic tobacco seeds" Biotechno		ineered antibodies in			
	80.	Brown et al., "Chimeric parvovirus B19 capsids for the presentation of foreign epitopes" Virol. (1994) 198:477-488.					
,	81.	Miyamura et al., "Parvovirus particles as platforms for protein presentation" <i>Proc. Natl. Acad. Sci. USA</i> (1994) 91:8507-8511.					
	82.	Moss, "Vaccinia virus: A tool for research and vaccine development" Science (1991) 252:1662-1667.					
	83.	Flexner et al. "Attenuation of live re human interleukin-2" Vaccines 88 (
C7	human interleukin-2" Vaccines 88 (1988) Cold Spring Harbor Laboratory, pp. 179-184. 84. Cockett et al., "High level expression of tissue inhibitor of metalloproteinases in Chinese harmster ovary cells using glutamine synthetase gene amplification" Bio/Technology (1990) 8:662-667.						
EXAMI	EXAMINER: DATE CONSIDERED:						

Form PTC)-1449		Docket Number 316082000121	Application Number 09/194,164			
INFOI	RMATI	ION DISCLOSURE CARATION C.	Applicant				
	IN	I AN APPLICATION O	Michael D). Dan et al.			
	U	Use several sheets if necessary	Filing Date November 20, 1998	Group Art Unknown			
•		STEAT & TRADERIT					
			OCUMENTS				
Examiner Initials	Ref. No.	Title					
Hilliais	85.	Douillard et al., "Monoclonal antibo	odies specific immunotherapy	of gastrointestinal tumors"			
CY		Hybridoma (1986) 5:Supp. 1:S139-	S149.				
	86.	Diener et al., "Specific immunosup	pression by immunotoxins co	ntaining daunomycin"			
	87.	Science (1986) 231:148-150. Greiner et al., "Recombinant interfe	area anhances monadonal and				
	67.	carcinoma lesions in vivo" Science		100dy-targeting of			
	88.	Wolff et al., "The use of monoclona	al anti-Thy, IgG, for the target	ting of liposomes to AKR-A			
		cells in vitro and in vivo" Biochem.	Biophys. Acta (1984) 802:259	9-273.			
	89. Brown et al., "Chimeric parvovirus B19 capsids for the presentation of foreign epitopes" Virology (1994) 198:477-488.						
	90.	Fletcher et al., "Recent advances in	the understanding of the bioc	hemistry and clinical			
	91.	pharmacology of interleukin-2" Lymphokine Res. (1987) 6:45-57.					
	91.	Rabinowich et al., "Functional analysis of mononuclear cells infiltrating into tumors: Lysis of autologous human tumor cells by cultured infiltrating lymphocytes" Cancer Res. (1987)					
		<i>47</i> :173-177.		, ,			
	92.	Rosenberg et al., "A new approach	to the adoptive immunotherap	y of cancer with tumor-			
	02	infiltrating lymphocytes" Science (1		1 1' 0 (II 0) ' 11 11			
	93.	Pizz et al., "Tumour regression after cancer. Preliminary report" Int. J. (rleukin 2 (IL-2) in bladder			
	94.	Neuwelt et al., "Modification of the		emotherapy of malignant			
		brain tumors" FASEB J. (1984) 43:2	214-219.				
.	95.	Baba et al., "Intracarotid infusion of	f leukotriene C ₄ selectively in	creases blood-brain barrier			
	06	permeability after focal ischemia in					
•	96.	Gennuso et al., "Effect of blood-bra central nervous system liposomal up					
	97.	Levin, "Relationship of octanol/wat	ter partition coefficient and me				
		capillary permeability" J. Med. Che					
	98.	Kostis et al., "Central nervous syste	m effects of HMG CoA reduc	tase inhibitors: Lovastatin			
		and pravastatin on sleep and cognitic Clin. Pharmacol. (1994) 34:989-996		ith hypercholesterolemia J.			
	99.	Bickel et al., "Pharmacologic effect		ediated pentide drug			
CY		delivery" Proc. Natl. Acad. Sci. US.					
EXAMIN	VER:	JungHY_	DATE CONSIDERED:	1/13/05			
EXAMINI conformar	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						

1						
!						
e						
ge						
i						
e ge						

EXAMINER: Change H & DATE CONSIDERED: 4/13/05

Form PTO-1449			Application Number 09/194,164						
INFORMATION DISCLOSURE CITATION O CAN AN APPLICATION			Applicant Michael D. DAN et al.						
Use several sheets if necessary)			Filing Date April 9, 1999 Group Art Unit 1642						
1	割				Mailing Date Novemb	per 23, 2004	•		
TRATE TRAD	U.S. PATENT DOCUMENTS								
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS									
Examiner Initials	Ref. No.	Date	Document No.		Country	Class	Subclass	Trans YES	lation NO
CY	1.	08/23/1989	EP 0 329 400	Eur					
CY	2.	11/26/1992	WO 92/20799	WI				Abstract	
_CY	3.	12/28/1995	WO 95/35374	WI				1	
		T	OTHE	R D	OCUMENTS	(includin	g author, title, Do	ite, Pertinent	Pages, Etc.)
Examiner Initials	Ref. No.	Title							
CY	4.	Boone, C. W Biol. 41:378-	'. et al., (1969). "Isola 392.	ation	of Plasma Membr	ane Fragment	s From Hela	Cells," <i>J.</i>	Cell.
	5.	Carter, W. G. et al., (1977). "Isolation and Partial Characterization of Galactoprotein a (LETS) and Galactoprotein b From Hamster Embryo Fibroblasts," <i>Biochem. Biophys. Res. Commun.</i> 76(2):299-308.							
	6.	Renaturation	(1986). "Effects of the of Proteins in Gels of Anal. Biochem. 157:	n the	e Recognition of P				onal
	7.	Hakomori, SI. (1989). "Aberrant Glycolsylation in Tumors and Tumor-Associated Carbohydrate Antigens," Adv. Cancer Res. 52:257-331.							
J	8.	Iida, N. et al., (1989). "A Sulfated Glucosylceramide From Rat Kidney," J. Biol. Chem. 264(10):5974-5980.							
	9. International Search Report mailed on March 17, 1998, for PCT Patent Application No. PCT/US97/08962 filed on May 22, 1997, 5 pages.								
	10. Kean, E. L. (1968). "Rapid, Sensitive Spectrophotometric Method for Quantitative Determination of Sulfatides," J. Lipid. Res. 9:319-327.						ition of		
CY	11.	Laemmli, U.	K. et al., (1973). "M	atura	tion of the Head o	f Bacteriopha	ge T4. I. DN	A Packagi	ng
EXAMI	NER:	Chris	oH.X		DATE CON	SIDERED:	13/05		
•			idered, whether or not the clude a copy of this form				line through the	citation if no	ot in
005156									

pa- 885176 PTO/SB/ 08 (2-92)

		Sheet 2 of 2			
)	Docket Number 316082000121	Application Number 09/194,164			
TON DISCLOSURE CITATION	Applicant				
N AN APPLICATION	Michael D. DAN et al.				
Use several sheets if necessary)	Filing Date April 9, 1999	Group Art Unit 1642			
	Mailing Date November 23, 2004				
	<u> </u>				
Events," J. Mol. Biol. 80:575-599.					
McKnight et al., (1990). "Human Mon Hybridoma 1(2):77-82.	oclonal Antibodies to Nuclear	Antigens," Human Antibod.			
Production and Immunological Proper	ties," Proceedings of the Americ				
Novapharm Biotech Inc., (January 200	00). Corporate Profile, 2 pages.				
Padlan, E. A. (1994). "Anatomy of the	Antibody Molecule," Molecula	er Immunol. 31(3):169-217.			
17. Press Release, (May 26, 1999). "Novopharm Biotech Inc., Announces Evidence Of Anti-Cancer Activity Utilizing Fully Human Antibodies In Pre-Clinical Animal Studies," <i>Novapharm Biotech</i> , 3 pages.					
		ential to Significantly Reduce			
		A Colorimetric Resorcinol-			
		ed Gangliotriaosylceramide			
	TON DISCLOSURE CITATION NAN APPLICATION Use several sheets if necessary) Events," J. Mol. Biol. 80:575-599. Maiti, P. K. et al., (1995). "Developmed Monoclonal Antibody H11 (NOVOM. McKnight et al., (1990). "Human Mone Hybridoma 1(2):77-82. McKnight, M. et al., (March 1993). "Neproduction and Immunological Proper Research Volume 34, page A 1223, Alendary Novapharm Biotech Inc., (January 200) Padlan, E. A. (1994). "Anatomy of the Press Release, (May 26, 1999). "Novo Activity Utilizing Fully Human Antiber pages. Press Release, (October 7, 1999). "Antispread of Breast Cancer." Novapharm Svennerholm, L. (1957). "Quantitative Hydrocholoric Acid Method," Biochem Tadano, K. et al. (1982). "Isolation and From Rat Kidney," J. Biol. Chem.257(Yiu, S. C. K. et al., (1992). "Polyisobu	TON DISCLOSURE CITATION NAN APPLICATION Use several sheets if necessary) Filing Date April 9, 1999 Mailing Date November 23, 2004 Events, " J. Mol. Biol. 80:575-599. Maiti, P. K. et al., (1995). "Development and Characterization of Pane Monoclonal Antibody H11 (NOVOMAb-G2)," Biotechnol.Internation McKnight et al., (1990). "Human Monoclonal Antibodies to Nuclear Hybridoma 1(2):77-82. McKnight, M. et al., (March 1993). "Monopharm-C, A Human Antica Production and Immunological Properties," Proceedings of the America Research Volume 34, page A 1223, Abstract No. 1330. Novapharm Biotech Inc., (January 2000). Corporate Profile, 2 pages. Padlan, E. A. (1994). "Anatomy of the Antibody Molecule," Molecula Press Release, (May 26, 1999). "Novopharm Biotech Inc., Announces Activity Utilizing Fully Human Antibodies In Pre-Clinical Animal Str.			

pa- 885176 PTO/SB/ 08 (2-92)

EXAMINER:

DATE CONSIDERED: